Shortages of pancreatic enzyme replacement therapy

That this House expresses deep concern over the ongoing shortage of pancreatic enzyme replacement therapy (PERT), a vital medication relied upon by 61,000 people across the UK, including those with pancreatic cancer and pancreatic exocrine insufficiency; notes with alarm that PERT shortages are predicted to continue until 2026, with no signs of resolution, leaving 82% of patients struggling to access their usual prescriptions, 80% forced to alter their diet or dosage, and many skipping meals altogether; recognises that without PERT, patients suffer from severe malabsorption, leading to malnutrition, muscle wasting, debilitating diarrhoea, and, in extreme cases, death by starvation; further notes the significant mental health impact of this crisis, with 51% of affected individuals experiencing increased stress, anxiety, and worry; and calls on the Secretary of State for Health and Social Care to urgently outline the steps being taken to address the root causes of the shortage, ensure a stable and adequate supply of PERT, and provide clear clinical guidance to support patients and healthcare professionals in managing this critical situation.